Oblique Therapeutics is excited to present the recent progress on its anti-Thioredoxin mAb program at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 - 14, Washington DC, USA

GOTHENBURG, Sweden, Oct. 14, 2021 /PRNewswire/ -- Oblique Therapeutics, a biotech focused on new medicines for severe diseases with large unmet medical needs, will present the recent progress on its anti-Thioredoxin mAb program at the Society for Immunotherapy of Cancer (SITC) Annual...

from PR Newswire: https://ift.tt/3BHhd88